177 related articles for article (PubMed ID: 16170021)
1. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin.
Abi-Habib RJ; Urieto JO; Liu S; Leppla SH; Duesbery NS; Frankel AE
Mol Cancer Ther; 2005 Sep; 4(9):1303-10. PubMed ID: 16170021
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Alfano RW; Leppla SH; Liu S; Bugge TH; Herlyn M; Smalley KS; Bromberg-White JL; Duesbery NS; Frankel AE
Mol Cancer Ther; 2008 May; 7(5):1218-26. PubMed ID: 18483309
[TBL] [Abstract][Full Text] [Related]
3. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Calipel A; Lefevre G; Pouponnot C; Mouriaux F; Eychène A; Mascarelli F
J Biol Chem; 2003 Oct; 278(43):42409-18. PubMed ID: 12917419
[TBL] [Abstract][Full Text] [Related]
4. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
5. Bacillus anthracis lethal toxin induces cell-type-specific cytotoxicity in human lung cell lines.
Kim NY; Kang CI; Hur GH; Yang JM; Shin S
J Appl Microbiol; 2014 May; 116(5):1334-43. PubMed ID: 24471528
[TBL] [Abstract][Full Text] [Related]
6. Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs.
Bardwell AJ; Abdollahi M; Bardwell L
Biochem J; 2004 Mar; 378(Pt 2):569-77. PubMed ID: 14616089
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
8. Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation.
Ouyang W; Guo P; Fang H; Frucht DM
J Biol Chem; 2017 Oct; 292(43):17919-17927. PubMed ID: 28893904
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
10. Anthrax lethal toxin increases superoxide production in murine neutrophils via differential effects on MAPK signaling pathways.
Xu L; Fang H; Frucht DM
J Immunol; 2008 Mar; 180(6):4139-47. PubMed ID: 18322225
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of human monocytic cell lines confers susceptibility to Bacillus anthracis lethal toxin.
Kassam A; Der SD; Mogridge J
Cell Microbiol; 2005 Feb; 7(2):281-92. PubMed ID: 15659071
[TBL] [Abstract][Full Text] [Related]
12. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
14. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
15. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
16. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Mazzio EA; Soliman KFA
Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
[TBL] [Abstract][Full Text] [Related]
17. Anthrax lethal and edema toxins fail to directly impair human platelet function.
Chauncey KM; Szarowicz SE; Sidhu GS; During RL; Southwick FS
J Infect Dis; 2012 Feb; 205(3):453-7. PubMed ID: 22158563
[TBL] [Abstract][Full Text] [Related]
18. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Gassenmaier M; Rentschler M; Fehrenbacher B; Eigentler TK; Ikenberg K; Kosnopfel C; Sinnberg T; Niessner H; Bösmüller H; Wagner NB; Schaller M; Garbe C; Röcken M
Am J Pathol; 2020 Oct; 190(10):2155-2164. PubMed ID: 32679231
[TBL] [Abstract][Full Text] [Related]
19. HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.
Ha SD; Lewin N; Li SSC; Kim SO
Cells; 2021 May; 10(5):. PubMed ID: 34064422
[TBL] [Abstract][Full Text] [Related]
20. Novel protein targeted therapy of metastatic melanoma.
Frankel AE; Koo HM; Leppla SH; Duesbery NS; Vande Woude GF
Curr Pharm Des; 2003; 9(25):2060-6. PubMed ID: 14552326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
